



Banzel® (rufinamide) – First-time generic

- On June 1, 2021, Hikma, Mylan, [Glenmark](#) and [Camber/Hetero](#) launched [AB-rated](#) generic versions of Eisai's [Banzel \(rufinamide\)](#) 200 mg and 400 mg tablets.
- Banzel is approved for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older and in adults.
- Rufinamide is also available generically as a [suspension](#) that carries the same indication as Banzel tablets.
- According to IQVIA™, Banzel tablets had annual sales of \$285.3 million for the 12-month period ending April 2021.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.